Historical Valuation
Neurocrine Biosciences Inc (NBIX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 15.73 is considered Undervalued compared with the five-year average of 21.92. The fair price of Neurocrine Biosciences Inc (NBIX) is between 141.98 to 218.46 according to relative valuation methord. Compared to the current price of 135.57 USD , Neurocrine Biosciences Inc is Undervalued By 4.52%.
Relative Value
Fair Zone
141.98-218.46
Current Price：135.57
4.52%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Neurocrine Biosciences Inc (NBIX) has a current Price-to-Book (P/B) ratio of 4.67. Compared to its 3-year average P/B ratio of 5.31 , the current P/B ratio is approximately -12.14% higher. Relative to its 5-year average P/B ratio of 5.98, the current P/B ratio is about -22.00% higher. Neurocrine Biosciences Inc (NBIX) has a Forward Free Cash Flow (FCF) yield of approximately 4.23%. Compared to its 3-year average FCF yield of 3.59%, the current FCF yield is approximately 18.00% lower. Relative to its 5-year average FCF yield of 3.09% , the current FCF yield is about 36.99% lower.
P/B
Median3y
5.31
Median5y
5.98
FCF Yield
Median3y
3.59
Median5y
3.09
Competitors Valuation Multiple
AI Analysis for NBIX
The average P/S ratio for NBIX competitors is 34.98, providing a benchmark for relative valuation. Neurocrine Biosciences Inc Corp (NBIX.O) exhibits a P/S ratio of 4.25, which is -87.85% above the industry average. Given its robust revenue growth of 27.78%, this premium appears sustainable.
Performance Decomposition
AI Analysis for NBIX
1Y
3Y
5Y
Market capitalization of NBIX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NBIX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is NBIX currently overvalued or undervalued?
Neurocrine Biosciences Inc (NBIX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 15.73 is considered Undervalued compared with the five-year average of 21.92. The fair price of Neurocrine Biosciences Inc (NBIX) is between 141.98 to 218.46 according to relative valuation methord. Compared to the current price of 135.57 USD , Neurocrine Biosciences Inc is Undervalued By 4.52% .
What is Neurocrine Biosciences Inc (NBIX) fair value?
NBIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Neurocrine Biosciences Inc (NBIX) is between 141.98 to 218.46 according to relative valuation methord.
How does NBIX's valuation metrics compare to the industry average?
The average P/S ratio for NBIX's competitors is 34.98, providing a benchmark for relative valuation. Neurocrine Biosciences Inc Corp (NBIX) exhibits a P/S ratio of 4.25, which is -87.85% above the industry average. Given its robust revenue growth of 27.78%, this premium appears sustainable.
What is the current P/B ratio for Neurocrine Biosciences Inc (NBIX) as of Jan 09 2026?
As of Jan 09 2026, Neurocrine Biosciences Inc (NBIX) has a P/B ratio of 4.67. This indicates that the market values NBIX at 4.67 times its book value.
What is the current FCF Yield for Neurocrine Biosciences Inc (NBIX) as of Jan 09 2026?
As of Jan 09 2026, Neurocrine Biosciences Inc (NBIX) has a FCF Yield of 4.23%. This means that for every dollar of Neurocrine Biosciences Inc’s market capitalization, the company generates 4.23 cents in free cash flow.
What is the current Forward P/E ratio for Neurocrine Biosciences Inc (NBIX) as of Jan 09 2026?
As of Jan 09 2026, Neurocrine Biosciences Inc (NBIX) has a Forward P/E ratio of 15.73. This means the market is willing to pay $15.73 for every dollar of Neurocrine Biosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Neurocrine Biosciences Inc (NBIX) as of Jan 09 2026?
As of Jan 09 2026, Neurocrine Biosciences Inc (NBIX) has a Forward P/S ratio of 4.25. This means the market is valuing NBIX at $4.25 for every dollar of expected revenue over the next 12 months.